Skip to the lineages
Regenerative Medicine

Does Insurance Cover A2M Injections?

Published November 16, 2026

Protocol: 8 steps in this guide
  1. How payers evaluate emerging biologic injections
  2. One commercial policy as an example
  3. Coverage policy versus prior authorization
  4. Billing code uncertainty
  5. Medical necessity and experimental exclusions
  6. Medicare versus commercial plans
  7. Written benefits verification checklist
  8. Appeals and out-of-pocket planning

Coverage depends on the plan, the product, the billing code and the diagnosis, so the only reliable answer is a written one from your insurer for your specific case. The public policies that address related products point toward limited coverage: Aetna’s policy on blood-derived products classifies platelet-rich plasma (PRP) and platelet-poor plasma injections for knee osteoarthritis as experimental, investigational or unproven, and one Medicare contractor’s policy does not cover PRP for joint or musculoskeletal conditions. Neither policy names A2M, so neither is a ruling on A2M as such. Plan to ask, in writing, before treatment.

How payers evaluate emerging biologic injections

Insurers pay for services they consider medically necessary under the terms of the plan. For Medicare, the standard comes from the Social Security Act, which, as quoted in Medicare’s Local Coverage Determination Platelet Rich Plasma Injections for Non-Wound Injections (L39058), “allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury.” In that policy, the contractor concluded: “The paucity of high quality studies, no clinical practice guideline endorsement, and no commercial coverage argue strongly against current PRP coverage.” The evidence an insurer would weigh for A2M is the thin evidence reviewed in what research shows about A2M injections for knee osteoarthritis.

One commercial policy as an example

Aetna’s Clinical Policy Bulletin 0784: Blood Products and Adipose Tissue Products states that it “addresses blood products and adipose tissue products for selected indications.” Under its “Experimental, Investigational, or Unproven” heading, it lists “Platelet-poor plasma or platelet-rich plasma injection for all indications,” naming osteoarthritis of the hip, knee and jaw joint among the examples. Points to keep in mind when reading it:

  • A2M is not named. The policy text does not mention alpha-2-macroglobulin. Some A2M products are made from platelet-poor plasma or from PRP, but whether Aetna would classify a given A2M service under this heading is a decision for Aetna, not for the patient or the clinic.
  • It is one insurer’s policy. Other insurers write their own, and plans can differ.
  • Check the dates. The bulletin shows a last review of 11/19/2025 and a next review date of 09/10/2026. A next-review date that has passed does not show that a newer version exists; ask the insurer which version applies.

Coverage policy versus prior authorization

A coverage policy says how the insurer treats a category of service. Prior authorization is approval, in advance, for a specific patient and service. A favorable policy does not guarantee payment, and prior authorization may still be subject to the plan’s terms and to the claim as billed. Ask whether prior authorization is required and whether an approval is a guarantee of payment.

Billing code uncertainty

Insurers decide claims by code. Aetna’s bulletin lists CPT code 0232T for “Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed,” and a separate code, 0481T, for autologous white blood cell concentrate. Neither describes an A2M product by name. Ask the clinic which code it will bill for your injection, and give that exact code to your insurer when you ask about coverage. A coverage answer about a different code does not apply.

Medical necessity and experimental exclusions

A plan may exclude services it classifies as experimental or investigational. Whether an A2M injection falls into that category for your plan is a question to put to the insurer directly. Regulatory status is a separate issue: an FDA approval question is covered in whether A2M injection therapy is FDA-approved for arthritis, and an insurer can decline to pay for a lawful service if it considers the service unproven.

Medicare versus commercial plans

In traditional Medicare, regional contractors can issue local coverage policies. The L39058 policy, administered by Noridian Healthcare Solutions for a group of western states and territories, is a non-coverage policy for PRP “as a means of managing musculoskeletal injuries and/or joint conditions.” It applies to PRP in that region, does not mention A2M, and does not decide coverage everywhere. The details of that policy and Medicare’s separate national coverage of PRP for chronic diabetic wounds are covered in what PRP treatment costs and what drives the price. Medicare Advantage and commercial plans have their own rules.

Written benefits verification checklist

Before treatment, get written answers to these questions:

Ask Why
Exact CPT or HCPCS code the clinic will bill Coverage decisions are code-specific
Diagnosis code (ICD-10) Coverage can depend on the condition
Product or kit name Separates A2M from ordinary PRP
Is this service covered under my plan? The core answer
Is it considered experimental or investigational? The category Aetna uses for PRP and platelet-poor plasma in osteoarthritis
Is prior authorization required? Avoids an unpaid claim
What will I owe out of pocket if it is denied? Sets your financial risk
Which policy version applies? Policies are revised

Appeals and out-of-pocket planning

If a claim or prior authorization is denied, ask the insurer in writing for the reason, the specific policy relied on and how to appeal. Plan as though you may pay the full price yourself unless you have a written approval. What that price might be, and how to get an itemized estimate, is covered in how much A2M joint injections cost.

Insurance coverage for A2M injections depends on your plan, code and diagnosis, and the public policies on related PRP and platelet-poor plasma injections for osteoarthritis classify them as unproven or non-covered, so treat A2M as a likely out-of-pocket cost unless your insurer confirms coverage in writing.

Cells linked to this one

This guide leads on to

Lineage D: Alpha-2-Macroglobulin (A2M)

What readers added

Add a remark

Your email address will not be published. Required fields are marked *